New melanoma drugs

The new drug, a LAG-3 antibody called relatlimab, has been approved treatment of unresectable or metastatic melanoma. The combo

Systemic treatment for melanoma has changed rapidly since the introduction of ipilimumab in 2024. 1 In the past decade, 12 new drugs have been approved for unresectable melanoma, along with four new approvals in the adjuvant setting and increasing research in neoadjuvant therapy.

Broadly, new Melanoma drugs fall into 2 categories: targeted therapy and immunotherapies. And neither of them is chemotherapy! The links behind

This past year brought new FDA approvals and new approaches in treatment of melanoma, confirming that the pace of drug development in this previously deadly

Background: Melanoma is one of the most aggressive cancers, and it is estimated that 76,250 men and women will be diagnosed with melanoma of the skin in the USA in 2024. Over the last few decades many drugs have been developed but only in 2024 have new drugs demonstrated an impact on survival in metastatic melanoma.

A new melanoma vaccine has shown its mettle in battling the deadly skin cancer in a new trial. People with advanced melanomas who received

Immune-focused drugs such as nivolumab and ipilimumab have greatly improved the survival of people battling advanced melanomas A new trial

This is an important treatment option for patients with metastatic melanoma for whom other treatments New Targeted Therapy Drugs: Unlike conventional

New Melanoma drugs fall into 2 categories: targeted therapy and immunotherapies. And neither of them is chemotherapy!